白细胞介素-1抑制剂：类风湿性多关节炎治疗的新选择 - Suppr

Suppr

超能文献

[Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis].

作者信息

Gabay C

机构信息

Département de médecine interne, Hôpital cantonal universitaire, Genève.

出版信息

Rev Med Suisse Romande. 2000 Jun;120(6):529-33.

PMID:11014098

Abstract

摘要

相似文献

[Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis].

Rev Med Suisse Romande. 2000 Jun;120(6):529-33.

The many worlds of reducing interleukin-1.

Arthritis Rheum. 2005 Jul;52(7):1960-7. doi: 10.1002/art.21107.

The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.

Rheum Dis Clin North Am. 2004 May;30(2):365-80, vii. doi: 10.1016/j.rdc.2004.01.005.

[Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].

Przegl Lek. 2002;59(11):916-8.

Cytokine blocker licensed for relief of rheumatoid arthritis symptoms.

Am J Health Syst Pharm. 2002 Feb 1;59(3):225-6. doi: 10.1093/ajhp/59.3.225.

[Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases].

Nihon Rinsho. 2004 Feb;62 Suppl 2:673-6.

Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.

J Rheumatol. 2004 Oct;31(10):2071-5.

Anakinra shows promise for treating patients with rheumatoid arthritis.

J Am Pharm Assoc (Wash). 2002 Jul-Aug;42(4):660-2. doi: 10.1331/108658002763029661.

Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.

Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I96-8. doi: 10.1136/ard.58.2008.i96.

Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.

Int J Clin Pract. 2003 Apr;57(3):231-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis].

Rev Med Suisse Romande. 2000 Jun;120(6):529-33.

The many worlds of reducing interleukin-1.

Arthritis Rheum. 2005 Jul;52(7):1960-7. doi: 10.1002/art.21107.

The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.

Rheum Dis Clin North Am. 2004 May;30(2):365-80, vii. doi: 10.1016/j.rdc.2004.01.005.

[Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].

Przegl Lek. 2002;59(11):916-8.

Cytokine blocker licensed for relief of rheumatoid arthritis symptoms.

Am J Health Syst Pharm. 2002 Feb 1;59(3):225-6. doi: 10.1093/ajhp/59.3.225.

[Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases].

Nihon Rinsho. 2004 Feb;62 Suppl 2:673-6.

Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.

J Rheumatol. 2004 Oct;31(10):2071-5.

Anakinra shows promise for treating patients with rheumatoid arthritis.

J Am Pharm Assoc (Wash). 2002 Jul-Aug;42(4):660-2. doi: 10.1331/108658002763029661.

Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.

Ann Rheum Dis. 1999 Nov;58 Suppl 1(Suppl 1):I96-8. doi: 10.1136/ard.58.2008.i96.

Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis.

Int J Clin Pract. 2003 Apr;57(3):231-4.

[Interleukin-1 inhibitors: a new alternative for the treatment of rheumatoid polyarthritis].

作者信息

Gabay C

机构信息

Département de médecine interne, Hôpital cantonal universitaire, Genève.

出版信息

Rev Med Suisse Romande. 2000 Jun;120(6):529-33.

PMID:11014098

Abstract

摘要